Quantcast

Latest Cutaneous lupus erythematosus Stories

2014-07-16 08:29:40

HERZLIYA, Israel, July 16, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that an overview of its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE) is included in an article titled, Novel Approaches to the Development of...

2014-07-16 08:28:09

--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE). http://photos.prnewswire.com/prnvar/20140715/127341 Following the successful completion of it phase 1 single dose safety study with RSLV-132, Resolve recently initiated a phase 2 study in lupus patients. The...

2014-07-08 12:28:28

Strengthens Collaboration between the Nation's Lupus Research Organizations NEW YORK, July 8, 2014 /PRNewswire/ -- The Lupus Research Institute (LRI) today announced that Team Life Without Lupus(®) is joining the Alliance for Lupus Research (ALR) fundraising program Walk with Us to Cure Lupus in New York City to help raise funds for lupus research. To that end, 100% of all funds raised by LRI's Team Life Without Lupus will go towards lupus research. The LRI and ALR are...

2014-07-07 11:39:51

European League Against Rheumatism Slower dose tapering and absence of positive serology reduce risk of flare A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that, for the majority of lupus patients who are in remission, it is possible to successfully stop immunosuppressant therapy without triggering a flare of their disease. Within two years, it was possible to stop the immunosuppressant in about 70% of clinically stable...

2014-06-11 12:25:52

Raises Thousands to Fund Research and Support for Lupus Community NEW YORK, June 11, 2014 /PRNewswire/ -- The Young Leaders of the S.L.E. Lupus Foundation celebrated the 10(th) anniversary of their highly successful "Night for the Fight" fundraiser. Diagnosed with lupus this past year, Bravo TV's reality TV star Ashlee White was among over 200 guests. HBO Def poet/singer/lupus activist Shanelle Gabrielle served as Master of Ceremonies for the evening. The event featured music by DJ...

2014-06-10 12:32:19

NEW YORK, June 10, 2014 /PRNewswire/ -- The Lupus Research Institute (LRI) launched the LRI Industry Council, a collaborative initiative founded with 13 leading pharmaceutical and biotechnology companies involved in lupus drug development. The LRI formed the new group to facilitate active collaboration among companies, research leaders, and patient advocates to overcome common obstacles in developing new treatments for lupus. The need for safer and more effective treatments is...

2014-06-09 12:30:42

CHICAGO, June 9, 2014 /PRNewswire-USNewswire/ -- Bruce Richardson, M.D., Ph.D., of The University of Michigan, has been selected as the second recipient of the Lupus Insight Prize. The award provides $200,000 for use in innovative research on lupus, an unpredictable and sometimes fatal autoimmune disease that affects an estimated 1.5 million Americans. The Prize is a collaborative initiative among the Alliance for Lupus Research (ALR), the Lupus Foundation of America (LFA), and the...

2014-06-09 08:30:13

ALBUQUERQUE, N.M., June 9, 2014 /PRNewswire/ -- Exagen Diagnostics, Inc., a leading medical diagnostic company focused in rheumatology, today announced the addition of the Avise SLE Prognostic panel to its testing services. http://photos.prnewswire.com/prnvar/20131028/LA05125LOGO Designed to supplement the Avise SLE+ Connective Tissue diagnostic, Avise SLE Prognostic is a comprehensive prognostic panel that helps physicians assess potential risk for lupus nephritis, neuropsychiatric...

2014-05-22 12:26:37

LONDON, May 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovationhttp://www.reportbuyer.com/pharma_healthcare/diseases/frontier_pharma_systemic_lupus_erythematosus_identifying_commercializing_first_in_class_innovation.html Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation SummaryThe Systemic Lupus...

2014-05-19 08:28:15

HERZLIYA, Israel, May 19, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of consultants Lee S. Simon, MD, FACP, FACR and David Isenberg, MD, for the planned Phase II trial for the Company's hCDR1 compound for the treatment of...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related